MarketLens
Sign Up

Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC)

6 months ago
SHARE THIS ON:

Why is Avoro Capital Advisors Making a Big Bet on Celcuity (CELC)

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

MacroGenics trades at a discount to its $327M cash position ($5.15/share), with a negative enterprise value. Its ADC/TCE pipeline and lorigerlimab offer multiple near-term catalysts, while Gilead's TC...
Stock News1 months ago

Playing The Biotech Breakout With Insiders

AbCellera Biologics and Alpha Cognition are highlighted for insider buying and revenue growth. ABCL's Phase 2 data for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts, with analyst targe...
Stock News2 months ago

Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript

Celcuity received FDA approval for REVTORPYK in advanced HR+/HER2- breast cancer, marking its first commercial product. The company outlined launch plans, potentially expanding treatment options in a ...

Breaking News

View All →

Top Headlines

View More →
Stock News47 minutes ago

Prediction: Nvidia's Revenue Growth Will Drive Shares to $400 Next Year

Stock News1 hour ago

Bill Ackman Built a $2.4 Billion Stake in Microsoft, Calling It a "Core Holding" Bought at a "Highly Compelling Valuation." Here's Why He's Betting Big on Big Tech.

Stock News2 hours ago

The Stock Market's Best Quarter of the Year Is About to Start. The S&P 500 Has Risen in 34 of the Last 41.

Stock News4 hours ago

Nvidia's Jensen Huang says AI CEOs have 'ulterior reasons' for warning about doomsday

Stock News6 hours ago

Meta's Muse TV ad is the latest sign that AI agents are going mainstream